Omalizumab Effectiveness in Severe Allergic Asthma with Multiple Allergic Comorbidities: A Post-Hoc Analysis of the STELLAIR Study
| dc.rights.license | open | en_US |
| dc.contributor.author | JUST, Jocelyne | |
| dc.contributor.author | THONNELIER, Celine | |
| dc.contributor.author | BOURGOIN-HECK, Melisande | |
| dc.contributor.author | MALA, Laurence | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | MOLIMARD, Mathieu | |
| dc.contributor.author | HUMBERT, Marc | |
| dc.contributor.author | INVESTIGATORS, Stellair | |
| dc.date.accessioned | 2021-11-22T08:40:02Z | |
| dc.date.available | 2021-11-22T08:40:02Z | |
| dc.date.issued | 2021-09-23 | |
| dc.identifier.issn | 1178-6965 (Print) 1178-6965 (Linking) | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/123889 | |
| dc.description.abstractEn | BACKGROUND: Immunoglobulin (Ig) E-mediated pathophysiological mechanisms are common in allergic diseases including severe allergic asthma (SAA). The anti-IgE monoclonal antibody omalizumab may be particularly beneficial for patients with SAA and multiple allergic comorbidities (AC) including perennial/seasonal rhinitis, conjunctivitis, atopic dermatitis (AD), and food allergy. METHODS: We conducted a post-hoc analysis of the patients from the STELLAIR study (n=872, 149 minors and 723 adults). The patients were classified based on the presence of multiple AC (≥3 AC or <3 AC) or AD as assessed by questionnaire. Response to omalizumab was assessed after 4-6 months (T(4-6)) and after 12 months (T(12)). Asthma response at T(4-6) was based on global evaluation of treatment effectiveness, reduction of ≥40% in annual exacerbation rate, and a combination of both. Asthma response at T(12) was based on change in yearly exacerbation and hospitalization rates. AC improvement at T(12) was based on patient perception. RESULTS: Patients with ≥3 AC demonstrated a higher combined response to omalizumab (74.7% vs 58.3%) at T(4-6) and had reduced yearly exacerbation and hospitalization rates (88.9% vs 77.4% and -94.0% vs -70.5%, respectively). Patients with ≥3 AC were more likely to show an improvement in their AC (85.3% vs 51.9%) at T(12). Results were similar in minors and adults. The presence of AD was associated with greater omalizumab effectiveness at T(4-6) and a greater AC improvement at T(12). Improvement of AD and food allergies at T(12) were 73.2% and 38.7%, respectively, in the population overall. CONCLUSION: This post-hoc analysis of the STELLAIR study shows that omalizumab is beneficial for all SAA patients and especially for patients with multiple AC or AD. In patients with ≥3 AC, omalizumab also improved AC outcomes. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution-NonCommercial 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/us/ | * |
| dc.subject.en | Ig-E | |
| dc.subject.en | Multiple allergic comorbidities | |
| dc.subject.en | Omalizumab | |
| dc.subject.en | Severe allergic asthma | |
| dc.title.en | Omalizumab Effectiveness in Severe Allergic Asthma with Multiple Allergic Comorbidities: A Post-Hoc Analysis of the STELLAIR Study | |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.2147/jaa.S310888 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 34588784 | en_US |
| bordeaux.journal | Journal of Asthma and Allergy | en_US |
| bordeaux.page | 1129-1138 | en_US |
| bordeaux.volume | 14 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | PharmacoEpi-Drugs | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.identifier.funderID | Novartis Pharma | en_US |
| hal.export | false | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Asthma%20and%20Allergy&rft.date=2021-09-23&rft.volume=14&rft.spage=1129-1138&rft.epage=1129-1138&rft.eissn=1178-6965%20(Print)%201178-6965%20(Linking)&rft.issn=1178-6965%20(Print)%201178-6965%20(Linking)&rft.au=JUST,%20Jocelyne&THONNELIER,%20Celine&BOURGOIN-HECK,%20Melisande&MALA,%20Laurence&MOLIMARD,%20Mathieu&rft.genre=article |
